Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

NCT ID: NCT04249323

Last Updated: 2022-02-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 110 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-27
• Study Completion Date: 2020-10-15

Brief Summary

This is a 3-part, first-in-human study of single ascending doses (SAD; Part 1) and multiple ascending doses (MAD; Part 2) of CORT113176 in healthy participants; Part 3 is an optional part to investigate whether CORT113176 ameliorates the effects of prednisone on various pharmacodynamic (PD) endpoints. The 3 parts may not be conducted entirely sequentially provided that this is justified by pharmacokinetic (PK) and safety data obtained from completed cohorts. The first MAD cohort will not start until data are available from at least 2 SAD levels to allow MAD administration in the fasted state, or until after a food-effect cohort has been dosed in the SAD phase to allow MAD administration in the fed state. The expected exposure for the daily MAD level at steady state (taking into consideration potential accumulation on repeat dosing) must not exceed the highest exposure considered to be safe and well tolerated during preceding SAD cohorts.

Conditions

Healthy Adults

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Part 1: SAD Cohorts A through H CORT113176

Cohorts will receive a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. Cohort A will receive a 50-mg dose in a fasted state. Cohort B will receive a ≤3-fold increase in dose from Cohort A in a fasted state; the dose will be determined after evaluation of safety and PK data for Cohort A. Subsequent cohorts will receive a ≤3-fold increase in CORT113176 dose from the previous cohort in a fasted or fed state; the dose and prandial state will be determined after evaluation of safety and PK data from previous cohorts. Following interim review of PK data, an alternative lipidic formulation may be administered beginning with Cohort B.

Group Type: EXPERIMENTAL

CORT113176 Lipid Capsule Formulation

Intervention Type: DRUG

CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Part 1: SAD Cohorts A through H Placebo

Cohorts will receive a single dose of placebo matching CORT113176 lipid capsule formulation by mouth on Day 1. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding SAD cohorts receiving CORT113176.

Group Type: PLACEBO_COMPARATOR

Placebo matching CORT113176 Lipid Capsule Formulation

Intervention Type: DRUG

Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Part 2: MAD Cohorts A through D CORT113176

Cohorts will receive once- or twice-daily doses of CORT113176 lipid capsule formulation by mouth for 14 days. The anticipated exposure will not exceed the highest exposure considered safe and well-tolerated during Part 1. The dose schedule and prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 2 will depend on data review for Part 1.

Group Type: EXPERIMENTAL

CORT113176 Lipid Capsule Formulation

Intervention Type: DRUG

CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Part 2: MAD Cohorts A through D Placebo

Cohorts will receive once- or twice-daily doses of placebo matching CORT113176 lipid capsule formulation by mouth for 14 days. The dose of placebo, prandial state, and choice of formulation will match that used for the corresponding MAD cohorts receiving CORT113176.

Group Type: PLACEBO_COMPARATOR

Placebo matching CORT113176 Lipid Capsule Formulation

Intervention Type: DRUG

Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Part 3: Single Dose Pharmacodynamic Effect

In Period 1, participants will receive a single dose of prednisone 25 mg tablet by mouth on Day 1 in a fasted or fed state. After a 7-day washout, in Period 2, participants will receive a single dose of prednisone as in Period 1 plus a single dose of CORT113176 lipid capsule formulation by mouth on Day 1 in a fasted or fed state. The dose of CORT113176 and the prandial state will be determined after evaluation of safety and PK data from Part 1. The choice of formulation of CORT113176 to be used in Part 3 will depend on data review for Part 1. Part 3 will proceed only if sufficiently high plasma CORT113176 exposure is achieved in Part 1.

Group Type: EXPERIMENTAL

CORT113176 Lipid Capsule Formulation

Intervention Type: DRUG

CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Prednisone

Intervention Type: DRUG

Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration

Interventions

CORT113176 Lipid Capsule Formulation

CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention Type: DRUG

Placebo matching CORT113176 Lipid Capsule Formulation

Placebo matching CORT113176 Lipid Capsule Formulation 10-200 mg for oral administration

Intervention Type: DRUG

Prednisone

Prednisone standard release tablets 1 x 20 mg plus 1 x 5 mg for oral administration

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Body mass index (BMI) 18.0 to 30.0 kg/m^2, inclusive
• Body weight ≤102 kg
• Willing to consume a high-fat breakfast, including pork
• Agrees to adhere to the contraception requirements of the protocol
• Additional criteria apply.

Exclusion Criteria

• Received any investigational drug or device in a clinical research study within the last 90 days
• History of any drug or alcohol abuse in the last 2 years; a confirmed positive drugs of abuse test result
• Regular alcohol consumption; a confirmed positive alcohol breath test at screening
• Current smoker; a confirmed positive breath carbon monoxide reading; current user of e-cigarettes or nicotine replacement products in the last 6 months
• Female of childbearing potential, pregnant or breastfeeding
• Have a pregnant partner
• Clinically significant abnormal clinical chemistry, hematology, or urinalysis result
• Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV)
• Active renal or hepatic disease
• History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal, neurological, or psychiatric disorder
• Any form of cancer in the last 5 years (exceptions apply)
• History of adrenal insufficiency
• Have a condition that could be aggravated by glucocorticoid and/or mineralocorticoid blockade
• Currently using glucocorticoids or a history of systemic glucocorticoid use in the last 12 months or 3 months for inhaled products
• Additional criteria apply.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Corcept Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sharan Sidhu, MBChb, BAO, MRCS, MFPM

Role: PRINCIPAL_INVESTIGATOR

Quotient Sciences

Locations

Quotient Sciences

Ruddington, Nottingham, United Kingdom

Countries

United Kingdom

Other Identifiers

2019-004258-27

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CORT113176-650

Identifier Type: -

Identifier Source: org_study_id